Abstract
Progression and metastasis of cancer proceeds in the context of a host response that includes interactions with immune cells that can both attenuate and paradoxically promote the process of metastasis. Growing evidence demonstrating the role of the inflammatory response in carcinogenesis is shedding light on a functional relationship between the host immune system and the malignant neoplasm. The interaction between neoplasm and the immune system can be described with the concepts of (1) cancer immunosurveillance, (2) cancer immunoediting, (3) complicity of the host cellular networks in lung tumorigenesis, and (4) tumor-mediated immunosuppression. Understanding the molecular mechanisms involved in inflammation and lung carcinogenesis provides insight for new drug development that target reversible, non-mutational events in the chemoprevention and treatment of lung cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
DeNardo, D.G., M. Johansson, and L.M. Coussens. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27: 11–8, 2008.
de Visser, K.E., A. Eichten, and L.M. Coussens. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24–37, 2006.
Balkwill, F., K.A. Charles, and A. Mantovani. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211–7, 2005.
Schwartz, R.S. Paul Ehrlich’s magic bullets. N Engl J Med 350: 1079–80, 2004.
Fenner, F. and G. Ada Frank. MacFarlane Burnet: two personal views. Nat Immunol 8: 111–3, 2007.
Dunn, G.P., L.J. Old, and R.D. Schreiber. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137–48, 2004.
Burnet, F.M. The Clonal Selection Theory of Acquired Immunity. London: Cambridge University Press, 1959.
O‘Mahony, D. and S. Kummar, and M.E. Gutierrez. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 23: 9022–8, 2005.
Dunn, G.P., L.J. Old, and R.D. Schreiber. The three Es of cancer immunoediting. Annu Rev Immunol 22: 329–60, 2004.
Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991–8, 2002.
Pham, S.M., R.L. Kormos, R.J. Landreneau, A. Kawai, I. Gonzalez-Cancel, R.L. Hardesty, B.G. Hattler, and B.P. Griffith. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 60: 1623–6, 1995.
Dickson, R.P., R.D. Davis, J.B. Rea, and S.M. Palmer. High frequency of bronchogenic carcinoma after single-lung transplantation. J Heart Lung Transplant 25: 1297–301, 2006.
Dieu-Nosjean, M.C., M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, N. Rabbe, L. Laurans, E. Tartour, L. de Chaisemartin, S. Lebecque, W.H. Fridman, and J. Cadranel. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26: 4410–7, 2008.
Kirk, C.J., D. Hartigan-O’Connor, and J.J. Mule. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 61: 8794–802, 2001.
Baratelli, F., H. Takedatsu, S. Hazra, K. Peebles, J. Luo, P.S. Kurimoto, G. Zeng, R.K. Batra, S. Sharma, S.M. Dubinett, and J.M. Lee. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med 6: 38, 2008.
Korst, R.J. and R.G. Crystal. Active, specific immunotherapy for lung cancer: hurdles and strategies using genetic modification. Ann Thorac Surg 76: 1319–26, 2003.
Ichiki, Y., M. Takenoyama, M. Mizukami, T. So, M. Sugaya, M. Yasuda, T. Hanagiri, K. Sugio, and K. Yasumoto. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 172: 4844–50, 2004.
Glassy, M.C., J. Yasutomi, and K. Koda. Lessons learned about the therapeutic potential of the natural human immune response to lung cancer. Expert Opin Investig Drugs 8: 995–1006, 1999.
Walser, T.C., X. Cui, J. Yanagawa, J.M. Lee, E. Heinrich, G. Lee, S. Sharma, and S.M. Dubinett. Smoking and lung cancer: The role of inflammation. Proceedings of the American Thoracic Society, 2008.
Hogg, J.C., F. Chu, S. Utokaparch, R. Woods, W.M. Elliott, L. Buzatu, R.M. Cherniack, R.M. Rogers, F.C. Sciurba, H.O. Coxson, and P.D. Pare. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645–53, 2004.
Taraseviciene-Stewart, L. and N.F. Voelkel. Molecular pathogenesis of emphysema. J Clin Invest 118: 394–402, 2008.
O‘Donnell, R., D. Breen, S. Wilson, and R. Djukanovic. Inflammatory cells in the airways in COPD. Thorax 61: 448–54, 2006.
Sevenoaks, M.J. and R.A. Stockley. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity–a common inflammatory phenotype? Respir Res 7: 70, 2006.
Dohadwala, M., S.C. Yang, J. Luo, S. Sharma, R.K. Batra, M. Huang, Y. Lin, L. Goodglick, K. Krysan, M.C. Fishbein, L. Hong, C. Lai, R.B. Cameron, R.M. Gemmill, H.A. Drabkin, and S.M. Dubinett. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 66: 5338–45, 2006.
Charuworn, B. Inflammation-mediated promotion of EMT in NSCLC: IL-1beta mediates a MEK/Erk- and JNK/SAPK-dependent down-regulation of E-cadherin. (American Thoracic Society 2006).
Baratelli, F., Y. Lin, L. Zhu, S.C. Yang, N. Heuze-Vourc’h, G. Zeng, K. Reckamp, M. Dohadwala, S. Sharma, and S.M. Dubinett. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 175: 1483–90, 2005.
Keshamouni, V.G., G. Michailidis, C.S. Grasso, S. Anthwal, J.R. Strahler, A. Walker, D.A. Arenberg, R.C. Reddy, S. Akulapalli, V.J. Thannickal, T.J. Standiford, P.C. Andrews, and G.S. Omenn. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 5: 1143–54, 2006.
Leng, Q., Z. Bentwich, and G. Borkow. Increased TGF-beta, Cbl-b and CTLA-4 levels and immunosuppression in association with chronic immune activation. Int Immunol 18: 637–44, 2006.
Huber, M.A., N. Kraut, and H. Beug. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548–58, 2005.
Lee, J.M., S. Dedhar, R. Kalluri, and E.W. Thompson. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973–81, 2006.
Thiery, J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740–6, 2003.
Dasari, V., M. Gallup, H. Lemjabbar, I. Maltseva, and N. McNamara. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am J Respir Cell Mol Biol 35: 3–9, 2006.
Krysan, K., J.M. Lee, M. Dohadwala, B.K. Gardner, K.L. Reckamp, E. Garon, M. St John, S. Sharma, and S.M. Dubinett. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol 3: 107–10, 2008.
Heinrich, E., M. Dohadwala, B. Charuworn, and S. Dubinett. Inflammation-dependent regulation of epithelial-mesenchymal transition in non-small cell lung cancer: the role of interleukin-1b. (Proceedings of the American Association for Cancer Research: 2008).
Mani, S.A., W. Guo, M.J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou, M. Brooks, F. Reinhard, C.C. Zhang, M. Shipitsin, L.L. Campbell, K. Polyak, C. Brisken, J. Yang, and R.A. Weinberg. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–15, 2008.
Yoshino, I., T. Kometani, F. Shoji, A. Osoegawa, T. Ohba, H. Kouso, T. Takenaka, T. Yohena, and Y. Maehara. Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer 110: 369–74, 2007.
Fondrevelle, M.E., B. Kantelip, R.E. Reiter, D.K. Chopin, J.P. Thiery, F. Monnien, H. Bittard, and H. Wallerand. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urologic Oncology, 2008.
Lee, G., M. Dohadwala, and S. Dubinett. Chronic exposure to Tobacco-Specific 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) Induces Epithelial-to-Mesenchymal Transition in Non-small Cell Lung Cancer (Proceedings of the American Thoracic Society, 2008).
Gershon, R.K. and K. Kondo. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18: 723–37, 1970.
Dye, E.S. and R.J. North. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J Exp Med 154: 1033–42, 1981.
Berendt, M.J. and R.J. North. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151: 69–80, 1980.
DiGiacomo, A. and R.J. North. T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J Exp Med 164: 1179–92, 1986.
Rakhmilevich, A.L. and R.J. North. Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2. Cancer Immunol Immunother 38: 107–12, 1994.
Antony, P.A. and N.P. Restifo. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25: 202–6, 2002.
Shevach, E.M. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193: F41–6, 2001.
Maloy, K.J. and F. Powrie. Regulatory T cells in the control of immune pathology. Nat Immunol 2: 816–22, 2001.
Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151–64, 1995.
Thornton, A.M. and E.M. Shevach. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164: 183–90, 2000.
Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu, and S. Sakaguchi. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969–80, 1998.
Thornton, A.M. and E.M. Shevach. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287–96, 1998.
Itoh, M., T. Takahashi, N. Sakaguchi, Y. Kuniyasu, J. Shimizu, F. Otsuka, and S. Sakaguchi. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162: 5317–26, 1999.
Papiernik, M., M.L. de Moraes, C. Pontoux, F. Vasseur, and C. Penit. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 10: 371–8, 1998.
Shevach, E.M. Regulatory T cells in autoimmmunity*. Annu Rev Immunol 18: 423–49, 2000.
Jordan, M.S., A. Boesteanu, A.J. Reed, A.L. Petrone, A.E. Holenbeck, M.A. Lerman, A. Naji, and A.J. Caton. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2: 301–6, 2001.
Sakaguchi, S. The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery. J Clin Invest 112: 1310–2, 2003.
Walker, M.R., D.J. Kasprowicz, V.H. Gersuk, A. Benard, M. Van Landeghen, J.H. Buckner, and S.F. Ziegler. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 112: 1437–43, 2003.
Sogn, J.A. Tumor immunology: the glass is half full. Immunity 9: 757–63, 1998.
Yoshino, I., T. Yano, M. Murata, T. Ishida, K. Sugimachi, G. Kimura, and K. Nomoto. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 52: 775–81, 1992.
Batra, R.K., Y. Lin, S. Sharma, M. Dohadwala, J. Luo, M. Pold, and S.M. Dubinett. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res 63: 642–6, 2003.
Woo, E.Y., H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Riley, L.R. Kaiser, and C.H. June. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168: 4272–6, 2002.
Alleva, D.G., C.J. Burger, and K.D. Elgert. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 153: 1674–86, 1994.
Huang, M., S. Sharma, J.T. Mao, and S.M. Dubinett. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157: 5512–20, 1996.
Liu, V.C., L.Y. Wong, T. Jang, A.H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B.A. Teicher, and C. Lee. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178: 2883–92, 2007.
Finke, J. and R. Bukowski, eds., Lung Cancer and Immune Dysfunction (Humana Press, 2004): 335–348.
Huang, M., M. Stolina, S. Sharma, J. Mao, L. Zhu, P. Miller, J. Wollman, H. Herschman, and S. Dubinett. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58: 1208–1216, 1998.
Stolina, M., S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P.W. Miller, J. Portanova, J.C. Lee, and S.M. Dubinett. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361–70, 2000.
Sharma, S., S.C. Yang, L. Zhu, K. Reckamp, B. Gardner, F. Baratelli, M. Huang, R.K. Batra, and S.M. Dubinett. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 65: 5211–20, 2005.
Katori, M. and M. Majima. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 49: 367–92, 2000.
Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871–5, 2001.
FitzGerald, G.A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2: 879–90, 2003.
Malkowski, M.G., S.L. Ginell, W.L. Smith, and R.M. Garavito. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 289: 1933–7, 2000.
Chandrasekharan, N.V., H. Dai, K.L. Roos, N.K. Evanson, J. Tomsik, T.S. Elton, and D.L. Simmons. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926–31, 2002.
Smith, W.L., D.L. DeWitt, and R.M. Garavito. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145–82, 2000.
Dubois, R.N., S.B. Abramson, L. Crofford, R.A. Gupta, L.S. Simon, L.B. Van De Putte, and P.E. Lipsky. Cyclooxygenase in biology and disease. FASEB J 12: 1063–73, 1998.
Aoyama, T., Y. Yui, H. Morishita, and C. Kawai. Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 81: 1784–91, 1990.
Ishihara, O., M.H. Sullivan, and M.G. Elder. Differences of metabolism of prostaglandin E2 and F2 alpha by decidual stromal cells and macrophages in culture. Eicosanoids 4: 203–7, 1991.
Kliewer, S.A., J.M. Lenhard, T.M. Willson, I. Patel, D.C. Morris, and J.M. Lehmann. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813–9, 1995.
Riedl, K., K. Krysan, M. Pold, H. Dalwadi, N. Heuze-Vourc’h, M. Dohadwala, M. Liu, X. Cui, R. Figlin, J.T. Mao, R. Strieter, S. Sharma, and S.M. Dubinett. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 7: 169–84, 2004.
Krysan, K., K. Reckamp, S. Sharma, M. Dohadwala, and S. Dubinett. PGE2 activates MAPK/Erk pathway in non-small cell lung cancer cells in an EGF receptor-independent manner. Cancer Res 65: 6275–81, 2005.
Tsujii, M. and R. Dubois. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 83: 493–501, 1995.
Hosomi, Y., T. Yokose, Y. Hirose, R. Nakajima, K. Nagai, Y. Nishiwaki, and A. Ochiai. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30: 73–81, 2000.
Wolff, H., K. Saukkonen, S. Anttila, A. Karjalainen, H. Vainio, and A. Ristimaki. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997–5001, 1998.
Khuri, F.R., H. Wu, J.J. Lee, B.L. Kemp, R. Lotan, S.M. Lippman, L. Feng, W.K. Hong, and X.-C. Xu. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-s86mall cell lung cancer. Clin Cancer Res 7: 861–7, 2001.
Soslow, R.A., A.J. Dannenberg, D. Rush, B.M. Woerner, K.N. Khan, J. Masferrer, and A.T. Koki. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637–45, 2000.
Hasturk, S., B. Kemp, S.K. Kalapurakal, J.M. Kurie, W.K. Hong, and J.S. Lee. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 94: 1023–31, 2002.
Tsubochi, H., N. Sato, M. Hiyama, M. Kaimori, S. Endo, Y. Sohara, and T. Imai. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer. Ann Thorac Surg 82: 1198–204, 2006.
Hida, T., Y. Yatabe, H. Achiwa, H. Muramatsu, K. Kozaki, S. Nakamura, M. Ogawa, T. Mitsudomi, T. Sugiura, and T. Takahashi. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761–4, 1998.
Brabender, J., J. Park, R. Metzger, P.M. Schneider, R.V. Lord, A.H. Holscher, K.D. Danenberg, and P.V. Danenberg. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 235: 440–3, 2002.
Achiwa, H., Y. Yatabe, T. Hida, T. Kuroishi, K. Kozaki, S. Nakamura, M. Ogawa, T. Sugiura, T. Mitsudomi, and T. Takahashi. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5: 1001–5, 1999.
Campa, D., S. Zienolddiny, V. Maggini, V. Skaug, A. Haugen, and F. Canzian. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25: 229–35, 2004.
Schreinemachers, D.M. and R.B. Everson. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–46, 1994.
Krysan, K., H. Dalwadi, S. Sharma, M. Pold, and S. Dubinett. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64: 6359–62, 2004.
Leahy, K.M., A.T. Koki, and J.L. Masferrer. Role of cyclooxygenases in angiogenesis. Curr Med Chem 7: 1163–70, 2000.
Gately, S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19: 19–27, 2000.
Dohadwala, M., R.K. Batra, J. Luo, Y. Lin, K. Krysan, M. Pold, S. Sharma, and S.M. Dubinett. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277: 50828–33, 2002.
Dohadwala, M., J. Luo, L. Zhu, Y. Lin, G.J. Dougherty, S. Sharma, M. Huang, M. Pold, R.K. Batra, and S.M. Dubinett. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 276: 20809–12, 2001.
Dy, G.K. and A.A. Adjei. Novel targets for lung cancer therapy: part II. J Clin Oncol 20: 3016–28, 2002.
Dy, G.K. and A.A. Adjei. Novel targets for lung cancer therapy: part I. J Clin Oncol 20: 2881–94, 2002.
Dubinett, S., S. Sharma, M. Huang, M. Dohadwala, M. Pold, and J. Mao., Cyclooxygenase-2 in lung cancer, in Progressive Experimental Tumor Research, ed. Bertino, J.R. (Basel: Basel Karger, 2003).
Lee, J.M., J.T. Mao, K. Krysan, and S.M. Dubinett. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol 3: 149–53, 2007.
Bhattacharya, M., K.G. Peri, G. Almazan, A. Ribeiro-da-Silva, H. Shichi, Y. Durocher, M. Abramovitz, X. Hou, D.R. Varma, and S. Chemtob. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci USA 95: 15792–7, 1998.
Breyer, R.M., C.R. Kennedy, Y. Zhang, and M.D. Breyer. Structure-function analyses of eicosanoid receptors. Physiologic and therapeutic implications. Ann N Y Acad Sci 905: 221–31, 2000.
Fujino, H. and J.W. Regan. Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? Trends Pharmacol Sci 24: 335–40, 2003.
Yang, L., Y. Huang, R. Porta, K. Yanagisawa, A. Gonzalez, E. Segi, D.H. Johnson, S. Narumiya, and D.P. Carbone. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 66: 9665–72, 2006.
Han, S., J.D. Ritzenthaler, B. Wingerd, H.N. Rivera, and J. Roman. Extracellular matrix fibronectin increases prostaglandin E2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2. J Biol Chem 282: 7961–72, 2007.
Lippman, S.M., N. Gibson, K. Subbaramaiah, and A.J. Dannenberg. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 11: 6097–9, 2005.
Reckamp, K.L., B.K. Gardner, R.A. Figlin, D. Elashoff, K. Krysan, M. Dohadwala, J. Mao, S. Sharma, L. Inge, A. Rajasekaran, and S.M. Dubinett. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 3: 117–24, 2008.
Reckamp, K.L., K. Krysan, J.D. Morrow, G.L. Milne, R.A. Newman, C. Tucker, R.M. Elashoff, S.M. Dubinett, and R.A. Figlin. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12: 3381–8, 2006.
Witta, S.E., R.M. Gemmill, F.R. Hirsch, C.D. Coldren, K. Hedman, L. Ravdel, B. Helfrich, R. Dziadziuszko, D.C. Chan, M. Sugita, Z. Chan, A. Baron, W. Franklin, H.A. Drabkin, L. Girard, A.F. Gazdar, J.D. Minna, and P.A. Bunn., Jr. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944–50, 2006.
Hogan, B.L. Bone morphogenetic proteins in development. Curr Opin Genet Dev 6: 432–8, 1996.
Okada, H. and R. Kalluri. Recapitulation of kidney development paradigms by BMP-7 reverses chronic renal injury. Clin Exp Nephrol 9: 100–1, 2005.
Kopp, J.B. BMP-7 and the proximal tubule. Kidney Int 61: 351–2, 2002.
Bellusci, S., R. Henderson, G. Winnier, T. Oikawa, and B.L. Hogan. Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis. Development 122: 1693–702, 1996.
Zeisberg, M., J. Hanai, H. Sugimoto, T. Mammoto, D. Charytan, F. Strutz, and R. Kalluri. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964–8, 2003.
Shao, J., B.M. Evers, and H. Sheng. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem 279: 14287–93, 2004.
Buchanan, F.G., D. Wang, F. Bargiacchi, and R.N. DuBois. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451–7, 2003.
Coffey, R.J., C.J. Hawkey, L. Damstrup, R. Graves-Deal, V.C. Daniel, P.J. Dempsey, R. Chinery, S.C. Kirkland, R.N. DuBois, T.L. Jetton, and J.D. Morrow. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 94: 657–62, 1997.
Pai, R., B. Soreghan, I.L. Szabo, M. Pavelka, D. Baatar, and A.S. Tarnawski. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289–93, 2002.
Yang, X.D., X.C. Jia, J.R. Corvalan, P. Wang, and C.G. Davis. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38: 17–23, 2001.
Hirata, A., S. Ogawa, T. Kometani, T. Kuwano, S. Naito, M. Kuwano, and M. Ono. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554–60, 2002.
Pold, M., L.X. Zhu, S. Sharma, M.D. Burdick, Y. Lin, P.P. Lee, A. Pold, J. Luo, K. Krysan, M. Dohadwala, J.T. Mao, R.K. Batra, R.M. Strieter, and S.M. Dubinett. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 64: 1853–60, 2004.
Williams, C.S., M. Tsujii, J. Reese, S.K. Dey, and R.N. DuBois. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589–94, 2000.
Torrance, C.J., P.E. Jackson, E. Montgomery, K.W. Kinzler, B. Vogelstein, A. Wissner, M. Nunes, P. Frost, and C.M. Discafani. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024–8, 2000.
Kim, G.E., Y.B. Kim, N.H. Cho, H.C. Chung, H.R. Pyo, J.D. Lee, T.K. Park, W.S. Koom, M. Chun, and C.O. Suh. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 10: 1366–74, 2004.
Chen, Z., X. Zhang, M. Li, Z. Wang, H.S. Wieand, J.R. Grandis, and D.M. Shin. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 5930–9, 2004.
Gadgeel, S.M., J.C. Ruckdeschel, E.I. Heath, L.K. Heilbrun, R. Venkatramanamoorthy, and A. Wozniak. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2: 299–305, 2007.
O‘Byrne, K.J., S. Danson, D. Dunlop, N. Botwood, F. Taguchi, D. Carbone, and M. Ranson. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 25: 3266–73, 2007.
Gridelli, C., C. Gallo, A. Ceribelli, V. Gebbia, T. Gamucci, F. Ciardiello, F. Carozza, A. Favaretto, B. Daniele, D. Galetta, S. Barbera, F. Rosetti, A. Rossi, P. Maione, F. Cognetti, A. Testa, M. Di Maio, A. Morabito, and F. Perrone. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8: 500–12, 2007.
Juni, P., L. Nartey, S. Reichenbach, R. Sterchi, P.A. Dieppe, and M. Egger. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021–9, 2004.
Solomon, D.H., S. Schneeweiss, R.J. Glynn, Y. Kiyota, R. Levin, H. Mogun, and J. Avorn. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–73, 2004.
Lilenbaum, R., M.A. Socinski, N.K. Altorki, L.L. Hart, R.S. Keresztes, S. Hariharan, M.E. Morrison, R. Fayyad, and P. Bonomi. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 24: 4825–32, 2006.
Chan, A.T., S. Ogino, and C.S. Fuchs. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131–42, 2007.
Edelman, M.J., D. Watson, X. Wang, C. Morrison, R.A. Kratzke, S. Jewell, L. Hodgson, A.M. Mauer, A. Gajra, G.A. Masters, M. Bedor, E.E. Vokes, and M.J. Green. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy – Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26: 848–55, 2008.
Lee, J.M., J. Yanagawa, K.A. Peebles, S. Sharma, J.T. Mao, and S.M. Dubinett. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66: 208–17, 2008.
Wislez, M., N. Fujimoto, J.G. Izzo, A.E. Hanna, D.D. Cody, R.R. Langley, H. Tang, M.D. Burdick, M. Sato, J.D. Minna, L. Mao, I. Wistuba, R.M. Strieter, and J.M. Kurie. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66: 4198–207, 2006.
Mao, J.T., M.C. Fishbein, B. Adams, M.D. Roth, L. Goodglick, L. Hong, M. Burdick, E.R. Strieter, C. Holmes, D.P. Tashkin, and S.M. Dubinett. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 12: 314–20, 2006.
Mao, J.T., X. Cui, K. Reckamp, M. Liu, K. Krysan, H. Dalwadi, S. Sharma, S. Hazra, R. Strieter, B. Gardner, and S.M. Dubinett. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 7: 30–9, 2005.
Peebles, K.A., J.M. Lee, J.T. Mao, S. Hazra, K.L. Reckamp, K. Krysan, M. Dohadwala, E.L. Heinrich, T.C. Walser, X. Cui, F.E. Baratelli, E. Garon, S. Sharma, and S.M. Dubinett. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther 7: 1405–21, 2007.
Walser, T.C., J. Yanagawa, J. Luo, M. Liu, L. Goodglick, L. Hong, M.C. Fishbein, J.D. Minna, J.W. Shay, R.M. Strieter, and S. Dubinett. Snail-induced and EMT-mediated early lung cancer development: Promotion of invasion and expansion of stem cell populations (Seventh Annual AACR International Conference, Frontiers in Cancer Prevention Research: 2008).
Yanagawa, J., T.C. Walser, L. Zhu, J. Luo, L. Hong, M.C. Fishbein, L. Goodglick, R.M. Strieter, S. Sharma, and S. Dubinett. The zinc-finger E-box-binding transcriptional repressor Snail promotes tumor progression and angiogenesis in non-small cell lung cancer (Seventh Annual AACR International Conference, Frontiers in Cancer Prevention Research: 2008).
Skillrud, D.M., K.P. Offord, and R.D. Miller. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 105: 503–7, 1986.
Parimon, T., J.W. Chien, C.L. Bryson, M.B. McDonell, E.M. Udris, and D.H. Au. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 712–9, 2007.
Wilson, D.O., J.L. Weissfeld, A. Balkan, J.G. Schragin, C.R. Fuhrman, S.N. Fisher, J. Wilson, J.K. Leader, J.M. Siegfried, S.D. Shapiro, and F.C. Sciurba. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 178: 738–44, 2008.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Lee, J.M. et al. (2009). Immunologic Mechanisms in Lung Carcinogenesis and Metastasis. In: Keshamouni, V., Arenberg, D., Kalemkerian, G. (eds) Lung Cancer Metastasis. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0772-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0772-1_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0771-4
Online ISBN: 978-1-4419-0772-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)